臨床研究等提出・公開システム

Effects of Highly Absorptive Curcumin (curcured) on knee osteoarthritis for three months (curcured on knee osteoarthritis for three months)

Effects of Highly Absorptive Curcumin (curcured) on knee osteoarthritis for three months (curcured on knee osteoarthritis for three months)

90

There were no significant differences in the baseline characteristics of the study patients in each of the three groups. The majority of patients were female, accounting for 77.8% in the high-dose of Curcured group, 88.5% in the low-dose of Curcured group, and 70.0% in the placebo group. The patient ages were also comparable across the three groups.

1st entry case: September 28, 2020 After 1 year Consent cases: 62 cases Completion cases: 44 cases Drop out cases: 3 cases After 2 years Consent cases: 90 cases Completion cases: 83 cases Drop out cases: 5 cases After 2 years Consent cases: 90 cases Completion cases: 83 cases Drop out cases: 7 cases Last case entry (90th case): July 21, 2022 Completion of last case: October 12, 2022

The adverse events of 3 groups for curcured90 mg, curcured30 mg and Placebo were in the following: Gastrointestinal disorders:1 case, 2 cases, 1 case Vertigo: 2 cases, 1 case, 0 cases Diarrhea: 2 cases, 0 cases, 1 case Lower limb edema: 2 cases,1 case, 1 case Itching: 1 case, 1 case, 1 case Radial nerve palsy 0 cases, 0 cases, 1 case

The declining trend in NSAIDs needs was significantly greater in high-dose Curcured group than in placebo group. The decrease of highly sensitive CRP was significantly greater in high-dose of Curcured than placebo group. In patients with KL Grade II, JOA and VAS scores improved significantly more in the high-dose Curcured group than in the placebo group. We did not find Curcured related adverse event during the study period.

Curcured has succeeded in proofing a potential for treating human knee OA, particularly at an early stage.

Dec. 01, 2023

Nov. 01, 2023

https://medicineinsights.info/index.php/cmi

No

do not open the publish

https://jrct.mhlw.go.jp/latest-detail/jRCTs051200058

Yamada Shigeru

National Hospital Organization Kyoto Medical Center

1-1 fukakusa mukaihata-cho, Fushimi-ku, Kyoto, Kyoto

chiyoji8887@gmail.com

Nakagawa Yasuaki

National Hospital Organization Kyoto Medical Center

1-1 fukakusa mukaihata-cho, Fushimi-ku, Kyoto, Kyoto

+81-75-641-9161

yasu0202nakagawa@gmail.com

Complete

Sept. 24, 2020

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

1) Medial knee osteoarthritis and KL classification II or III, 2) over 40 years. 3) consent of patient , 4) outpatient

1)Severe renal dysfunction or dialysis 2)severe liver dysfunction or liver cirrhosis 3)severe cardiovascular diseases 4)severe cerebrovascular dysfunction 5)severe diabetes mellitus 6)curcumin abuse patients 7)previous knee surgery or intraarticular injection for experimental period or steroid intraarticular injection before 2 months or steroid oral intake before 4 weeks 8)patient who must be excluded by the scientific responsible doctor

Both

knee osteoarthritis

Highly Absorptive Curcumin (curcured) on knee osteoarthritis for three months

knee joint medial type

curcumin, oral intervention

D020370

D046650

JKOM, VAS, JOA knee OA score, dependence of NSAIDs

Time up and go, knee range of motion biochemical analysis of blood, blood concentration of curcumin

+81-744-29-8835

Sept. 04, 2020

none